FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Mahony Susan						2. Issuer Name <b>and</b> Ticker or Trading Symbol  LILLY ELI & CO [ LLY ]								(Che	5. Relationship of Report (Check all applicable) Director			10% Owner	
(Last)	Last) (First) (Middle) LILLY CORPORATE CENTER					3. Date of Earliest Transaction (Month/Day/Year) 01/27/2017								, x	X Officer (give title Other (specify below)  SVP & Pres., Lilly Oncology				
(Street) INDIANAPOLIS IN 46285 (City) (State) (Zip)				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(5	,	(Zip)	n-Deri	 vativ	e Se	curities	S Acc	nuired.	Disi	nosed o	f. or F	enef	icially	/ Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				saction	ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code (	3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			or 5. Amount of Securities Beneficially Owned Follow		Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) (D)	or F	Price		Transaction(s) (Instr. 3 and 4)		[	Instr. 4)
Common Stock 01/27/					7/201	2017		A		19,243 A		A (	\$75.38	86,308			D		
Common Stock															1,0	684		I	401(k)
Common Stock 01/27/					7/201	2017		A		2,030	) ]	A	\$75.38	13,509			(1)	oy nusband	
Common Stock															1,6	673		$\mathbf{I}^{(1)}$ l	401(k) - by nusband
		-	Table II -								osed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		ı of E		Expiration	b. Date Exercisa Expiration Date Month/Day/Yea		7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		urity	3. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of Sh	mber ares					
Restricted	(2)	01/27/2017			A		21,326		02/01/201	.8 l o	2/01/2018	Commo	<sup>n</sup> 21	.326	\$0	21.326	5	D	

## **Explanation of Responses:**

- 1. Reporting person disclaims beneficial ownership of these shares.
- 2. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

## Remarks:

Tiffany R. Benjamin for Susan Mahony, authorization on file

01/31/2017

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.